If something feels different down there since you started the shot, you are not imagining it and you are not the only one quietly looking this up. Some women on a GLP-1 (semaglutide, sold as Ozempic and Wegovy; tirzepatide, sold as Mounjaro and Zepbound) notice vaginal dryness, irritation, changes in discharge, or shifts in their period. Here is the honest part: most of these are reported, not proven, and none are on the FDA list for these drugs. Where there is a likely reason, it usually points to fast weight loss, not the medicine itself. And the yeast infections people search for under "Ozempic side effects" actually belong to a different class of drug. Two things are genuinely worth acting on: period changes that can mean returning fertility, and a contraception note specific to tirzepatide. This is general information, not medical advice. Talk to your prescriber about your own situation.
What women are actually noticing
First, the reassuring part: this is one of the things women look up most after starting the shot, almost always in private. You are allowed to ask about it out loud.
In patient forums, clinic conversations, and health articles, women on a GLP-1 describe a handful of intimate changes. None are listed in the prescribing information as effects of the drug, and most can be explained by other things happening at the same time. They come up often enough, though, to deserve naming plainly:
- Dryness and irritation. A dry, tender feeling, sometimes with discomfort during sex.
- Yeast or BV-type symptoms. Itching, unusual discharge, or odor that women blame on the medication.
- Discharge changes. More, less, or just different from your normal.
- Period changes. Cycles becoming irregular, lighter or heavier, or returning after they had stopped. These tend to cluster during fast weight loss and settle as your weight steadies.
- Changes in sex itself. A few reports of less lubrication or sensation, including one published case of difficulty reaching orgasm.
You may also see numbers floating around, like dryness affecting "up to about 10%" of women on these drugs. Those figures are not drawn from any trial or dataset we can point to, so we treat them as a sense of the conversation, not as data. The honest summary: these symptoms are reported and under-studied, not measured.
What the evidence actually says
When you move from stories to evidence, the picture gets thin fast, and what evidence there is points away from the medicine being the cause.
The clearest place to look is the drug label. The FDA adverse-reaction list in the semaglutide (Ozempic) prescribing information contains no vaginal, genital, or yeast (mycotic) entries at all. The documented reactions are mostly gastrointestinal, alongside things like gallstones, diabetic eye changes, pancreatitis, kidney injury, and low blood sugar. In plain terms: vaginal and genital symptoms are not an established labeled effect of this class. If they were a recognized reaction to the drug, this is exactly where they would show up.
Sexual function has only been looked at around the edges. There is one published case report, a single woman who developed trouble reaching orgasm after starting a GLP-1, and even there the authors say plainly that "sexual dysfunction is not a known side effect of GLP-1 agonists". A separate signal has been raised in insurance-claims data, but that kind of analysis gets tangled up with the other health conditions these women have, and cannot show the drug is the cause.
So this is genuinely under-studied ground. There is no strong, GLP-1-specific evidence that the medicine itself causes vaginal infections or dryness.
Why fast weight loss is the likelier reason
If these symptoms are real for the women feeling them, and they are, what could be behind them? The most honest answers are still hypotheses, and the strongest is weight loss rather than any direct action of the drug:
- Lower estrogen from losing fat. Body fat actually makes estrogen. When you lose fat quickly, estrogen can drop, and low estrogen is a well-known cause of vaginal dryness. It is the same reason dryness is common around menopause. That points to losing weight fast, which these drugs cause, rather than something about the molecule.
- Cycle changes from a big energy deficit. A large, fast calorie deficit shifts your reproductive hormones, which can make periods irregular, lighter, heavier, or, if they had stopped, return. This tracks with the pace of weight loss, which is why it tends to settle once your weight stabilizes.
- Changing infection risk with diabetes, direction unclear. For women with diabetes, better blood-sugar control could in theory change how prone you are to infections, but which way is genuinely unclear, and it would not apply if you take the drug purely for weight loss.
- Microbiome and hygiene shifts get suggested sometimes, but this is speculation, not something the evidence supports.
The thread tying these together is that the plausible reasons sit downstream of weight loss, not in the GLP-1 itself, and every one is still unproven.
The big mix-up: yeast infections are a different drug
This is the single most important thing to get right on this page, because the public conversation gets it wrong all the time, and you deserve the accurate version.
Genital yeast infections are a real, labeled, well-established side effect, but of SGLT2 inhibitors, a different class of diabetes medication. That group includes canagliflozin (Invokana), dapagliflozin (Farxiga), and empagliflozin (Jardiance). These drugs work by making the kidneys send extra sugar out in the urine, which leaves a sugar-rich environment that yeast loves. It happens often enough to sit right on the drug labels for that class, and a review of FDA adverse-event reports found genital fungal infections strongly and specifically tied to SGLT2 inhibitors. In the trials, female genital yeast infections affected several times more women on an SGLT2 inhibitor than on placebo. The FDA has also flagged a rare but serious infection (Fournier's gangrene) with this class.
GLP-1 medications do not send sugar into the urine, so this mechanism, and this risk, does not carry over. A pharmacist-reviewed explainer makes the same point directly: yeast infections are not associated with GLP-1 drugs, and the genital-yeast risk people have heard about comes from SGLT2 inhibitors.
Why does this matter for you? Because both kinds of drug are used for type 2 diabetes, and many women search "does Ozempic cause yeast infections" having picked up a risk that really belongs to Farxiga or Jardiance. The two get blurred together constantly, and that mix-up is a big part of why GLP-1 drugs carry a reputation here the evidence does not back up. If yeast infections are what is worrying you, the question that matters is which class of drug you are on.
The two things genuinely worth acting on
Most of this page is about calming a worry the evidence does not support. But there are two real, evidence-backed points worth carrying with you:
- A returning period can mean returning fertility. Weight loss can restore ovulation and fertility, good news for many women but easy to be caught off guard by. Pregnancy on a GLP-1 is not recommended, so a period that comes back is a real reason to revisit birth control with your clinician. This matters especially with PCOS, where weight loss can improve cycles and ovulation. For more on how the shot lands differently for women, see what is different for women on the shot.
- A contraception note specific to tirzepatide. If you are on tirzepatide (Mounjaro or Zepbound) and take a birth control pill, this one matters. The tirzepatide prescribing information advises that tirzepatide can make oral hormonal contraceptives less effective, and recommends either adding a barrier method (like condoms) or switching to a non-oral method for 4 weeks after you start and for 4 weeks after each dose increase. This is tirzepatide-specific. It does not apply to semaglutide (Ozempic, Wegovy). Your prescriber can tell you in one conversation what it means for you.
When to get checked
Whatever the cause, vaginal symptoms that bother you deserve attention on their own terms, not because the shot is to blame, but because they are common, treatable, and worth getting looked at:
- Yeast-infection signs: itching, thick white discharge, and pain with peeing or sex, especially if they keep coming back or are not clearing up with the usual care.
- Bacterial-vaginosis signs: thin grey discharge with a fishy odor.
- Dryness or pain with sex that is getting in the way of your comfort or your relationship. This is treatable, and you do not have to just live with it.
- Periods that change a lot, become irregular, or go missing. Worth a conversation, and worth the contraception check above.
Most vaginal symptoms are common, harmless, and easy to treat, and the only reason to know the urgent signs is so you can tell the difference quickly and stop worrying about the ordinary ones. For where this sits among the other serious GLP-1 side effects, see the hub, and for the milder, better-documented effects, see the side effects overview.
Questions people ask at 11pm
Do GLP-1 drugs like Ozempic cause vaginal yeast infections? There is no good evidence that they do, and yeast or genital infections are not in the GLP-1 (semaglutide) label at all. The risk you have probably heard about belongs to a different class of diabetes drug, SGLT2 inhibitors like Farxiga and Jardiance, which put sugar in the urine. GLP-1 drugs do not, so that risk does not carry over.
Why might I feel dry down there on a GLP-1, then? The likeliest reason is fast weight loss rather than the drug itself. Losing fat quickly can lower estrogen, and low estrogen is a well-known cause of vaginal dryness. It is plausible but unproven, and the symptom is reported but under-studied. Worth raising with your clinician, who can treat the dryness whatever is causing it.
Why has my period changed since starting the shot? Fast weight loss and a big calorie deficit can shift your hormones, making periods irregular, lighter, heavier, or, if they had stopped, return. This usually settles as your weight steadies. The practical thing to hold onto: a returning period can mean returning fertility, pregnancy on a GLP-1 is not recommended, and if you are on tirzepatide your pill may be less reliable, so talk to your clinician about contraception.
How we reviewed this: written from authoritative sources, including the semaglutide (Ozempic) prescribing information, the tirzepatide prescribing information, a published case report on sexual function and GLP-1 agonists, a pharmacovigilance review of genital fungal infections and SGLT2 inhibitors, and a pharmacist-reviewed explainer on GLP-1 drugs and yeast infections. This is an under-studied topic, and much of what circulates online confuses GLP-1 drugs with SGLT2 inhibitors or with the effects of rapid weight loss. Where the evidence is thin or pointing elsewhere, we say so plainly rather than implying a drug effect the data does not support. See our editorial and review policy and sourcing standards.
Every medical claim above is cited to a primary source such as an FDA label, the NIH, or a named clinical trial. See how we review and our sourcing & fact-check standards.